Pediatric Adrenocortical Cancer (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Pediatric Adrenocortical Cancer (ACC) is a rare neoplasm that affects the adrenal glands in children. The adrenal glands, located above the kidneys, produce hormones that regulate various physiological processes, including blood pressure, heart rate, and metabolism. Clinical presentation of pediatric ACC includes weight gain, hypertension, and changes in skin pigmentation. The genomic landscape of pediatric ACC is characterized by copy-neutral loss of heterozygosity on chromosomes 11 and 17, which is associated with germline TP53 pathogenic variants, insulin-like growth factor-2 overexpression, and somatic mutations in ATRX and CTNNB1. Li-Fraumeni Syndrome, an autosomal dominant familial cancer syndrome, is most commonly associated with pediatric ACC. Pediatric ACCs are more likely to be functional, often presenting with excess androgen production. The 5-year survival rate for pediatric ACC ranges from 30-70%, depending on disease presentation. The bimodal age distribution of pediatric ACC peaks under age five and after ten years, with 46% of diagnoses occurring in children under four years of age. The international TNM staging system classifies 44% of patients as Stage I, 25% as Stage II, 13% as Stage III, and 17% as Stage IV. The primary treatment for pediatric ACC is surgical resection, with adjuvant chemotherapy often employed depending on the results.

• Pediatric Adrenocortical Cancer (ACC) incidence ranges from 0.3 to 0.58 per million children under 15 years of age.

 

Thelansis’s “Pediatric Adrenocortical Cancer (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pediatric Adrenocortical Cancer (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Pediatric Adrenocortical Cancer (ACC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pediatric Adrenocortical Cancer (ACC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pediatric Adrenocortical Cancer (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033